Background
==========

Gastric cancer is one of the most diagnosed malignant tumors and the third most common cause of cancer associated death globally \[[@b1-medscimonit-25-4705]\]. The general prognosis of gastric cancer is poor because of advanced stages when first diagnosis for most patients \[[@b2-medscimonit-25-4705],[@b3-medscimonit-25-4705]\].

The molecular mechanism of the occurrence and development of gastric cancer has not yet been fully elucidated. Recent studies have shown that overexpression of oncogenes and low expression of tumor suppressor genes play an important role in the occurrence and development of gastric cancer \[[@b4-medscimonit-25-4705],[@b5-medscimonit-25-4705]\]. It has been reported in the literature that lysophosphatidic acid receptor (LPA) is highly expressed in human malignant tumors and is associated with poor clinical characteristics and prognosis \[[@b6-medscimonit-25-4705]--[@b8-medscimonit-25-4705]\]. LPA2 protein is encoded by the *LPA* gene, which is located in the 19.62--19.62 region of human chromosome 19. LPA2 is a G protein-coupled receptor which can bind with its ligand and then activate LPA signaling pathway, thereafter, promote cell proliferation and malignant transformation. It has been reported that LPA2 is highly expressed in solid tumors such as breast cancer and participates in biological behaviors of cancer cells proliferation and invasion \[[@b6-medscimonit-25-4705]\]. Krüppel-like factor 5 (KLF5), the basic transcription element-binding protein 2 (BTEB2) in eukaryotes, is a zinc finger protein transcription factor, also known as intestinal-enriched KLF (IKLF). KLF5 can further regulate its targets genes expression by activating or inhibiting the transcription of target genes, and plays an important role in cell proliferation, differentiation, and apoptosis \[[@b9-medscimonit-25-4705],[@b10-medscimonit-25-4705]\]. However, the expression of LPA2 and KLF5 in gastric cancer and their relationship with the occurrence and development of gastric cancer have rarely been reported.

Material and Methods
====================

Patients
--------

Fifty-one gastric cancer patients seen from March 2010 to March 2016 in Second People's Hospital of Jiuquan City, Gansu Province were included in this study. All the patients had pathological diagnosed gastric adenocarcinoma. In addition, 13 cases of normal gastric mucosa and 21 cases of gastric intraepithelial neoplasia (GIN) were selected for inclusion, including 12 cases of low-grade GIN and 9 cases of high-grade GIN. The general characteristics of the included cases presented in [Table 1](#t1-medscimonit-25-4705){ref-type="table"}. This study was approved by the ethical committee of the Second People's Hospital of Jiuquan City, Gansu Province. The research related to human use has been complied with all the relevant national regulations, institutional policies, and was performed in accordance with the tenets of the Helsinki Declaration, and was approved by the Second People's Hospital of Jiuquan City, Gansu Province Institutional Review Board.

Methods
-------

### Instruments and equipment

The following instruments and reagents were used in this study: 1) rabbit anti-human LPA2 polyclonal antibody (Beijing Booshen Biotechnology Company, dilution number: bs-2881R, 1: 500); 2) anti-human KLF5 polyclonal antibody (Abcam, UK, 1: 600 dilution number: ab 24331); (3) instant SP9001 Kit (Beijing Zhongshan Jinqiao Biotechnology Company); 4) DAB enzyme substrate color reagent Kit (Beijing Zhongshan Jinqiao Biotechnology Company); 5) paraffin slicer (Leica Camera AG; Model: SHANDONAS-325); 6) OLYMPUSBX-40 microscope (Olympus); 7) constant-temperature bath (Grant Instruments), and 8) water purification system (Millipore Corporation).

### Tissue microarray

The pathology slices were reviewed, the tissues were located under the microscope, and the location of the wax blocks was marked to determine the sampling site ([Figure 1](#f1-medscimonit-25-4705){ref-type="fig"}). A 2-mm hollow wax pattern was made with a tissue chip die. The tissue wax core was taken out at the marker site of the wax block by a tissue chip sampler with an inner diameter of 2 mm. The wax core was placed into the hole of the hollow wax pattern. A 6×7 tissue microarray was made, and the wax block of the tissue chip was sliced continuously at a thickness of 4 microns. The wax core was attached to the APES anti-stripping slide ([Figure 2](#f2-medscimonit-25-4705){ref-type="fig"}).

### Immunohistochemistry

After dewaxing and gradient alcohol hydration, pH 6.0 citric acid was used to repair antigen under high temperature and high pressure. Then 3% hydrogen peroxide was used to remove endogenous enzyme activity for 10 minutes. Reagent A was applied and sealed at room temperature for 10 minutes. Primary and secondary antibodies were added by dripping after the antigen was retrieved. The tissues were developed and mounted for microscopic examination.

### Determination of positive results

Two pathologists read the slices independently. Five visual fields were selected under high power microscopy to calculate the proportion of LPA positive cells in each visual field. The main positive cells were brown-yellow granules in cytoplasm/membrane. Results were qualitatively described as follows: positive cells \<5% (−), positive cells 5\~25% (+), positive cells 25\~50% (++), positive cells (++), positive cells (++) and positive cells \>50% (+++).

Statistical analysis
--------------------

Data in the present work was analyzed through Stata 11.0 statistical software (Stata Corporation, College Station, TX, USA). Measurement data and counted data expressed as mean ± standard deviation and rate. Comparisons were made by Fisher's exact test and F test. Differences were considered significant at *P*\<0.05.

Results
=======

LPA 2 expression in different groups
------------------------------------

LPA2 was mainly expressed in the cytoplasm and cell membrane with brown granular ([Figure 3](#f3-medscimonit-25-4705){ref-type="fig"}). The positive expression rate was 89.5% (17 out of 19), 81.3% (13 out of 16), 25.0% (4 out of 16), 33.3% (3 out of 9), 25.0% (3 out of 12), and 23.1% (3 out of 13) for poor, moderate, well differentiation gastric adenocarcinoma, high grade GIN, low grade GIN, and normal gastric tissue respectively with statistical difference (*P*\<0.05) ([Table 2](#t2-medscimonit-25-4705){ref-type="table"}). The mRNA relative expression level of LPA2 was examined by real-time polymerase chain reaction (PCR) assay. The results showed that the LPA2 mRNA level of gastric adenocarcinoma and GIN were 0.045±0.018 and 0.021±0.009 respectively with statistical difference (*P*\<0.05).

Correlation between LPA2 expression and clinicopathological features
--------------------------------------------------------------------

LPA2 positive expression was not correlated with age, sex, location, diameter, or histological grade of the patients (*P*\>0.05), but was correlated with depth of invasion, Lauren classification, vascular invasion, lymph node metastasis, and clinical stage (*P*\<0.05) ([Table 3](#t3-medscimonit-25-4705){ref-type="table"}).

KLF5 expression in different groups
-----------------------------------

KLF5 was mainly expressed in the cytoplasm, brown granular ([Figure 4](#f4-medscimonit-25-4705){ref-type="fig"}). The positive expression rate was 78.9% (15 out of 19), 75.0% (12 out of 16), 75.0% (12 out of 16), 66.7% (6 out of 9), 58.3% (7 out of 12), and 38.5% (5 out of 13) for poor, moderate, well differentiation gastric adenocarcinoma, high grade GIN, low grade GIN, and normal gastric tissue respectively with statistical difference (*P*\<0.05) ([Table 4](#t4-medscimonit-25-4705){ref-type="table"}). The mRNA of relative expression level of KLF5 was examined by real-time PCR assay. The results showed that the KLF5 mRNA level of gastric adenocarcinoma and GIN were 0.64±0.21 and 0.62±0.20 respectively without statistical difference (*P*\>0.05).

Correlation between KLF5 expression and clinicopathological features
--------------------------------------------------------------------

The positive expression of KLF5 protein was not correlated with age, sex, tumor location, tumor diameter, histological grade, depth of invasion, Lauren classification, vascular invasion, regional lymph node metastasis, or clinical stage (*P*\>0.05), ([Table 5](#t5-medscimonit-25-4705){ref-type="table"}).

LPA2, KLF5 expression and prognosis
-----------------------------------

There was no correlation between LPA2 (HR=1.84, 95% CI: 0.89--3.80, *P*\>0.05), KLF5 (HR=1.13, 95% CI: 0.53--2.36, *P*\>0.05) expression and patients' overall survival ([Figure 5](#f5-medscimonit-25-4705){ref-type="fig"}). For disease free survival (DFS), the difference was also not statistical different between LPA2 (HR=1.34, 95% CI: 0.68--3.12), KLF5 (HR=1.05, 95% CI: 0.46--2.14) positive and negative groups.

Discussion
==========

Gastric cancer is one of the most diagnosed malignant tumor of digestive system and the third leading cause of cancer related death \[[@b11-medscimonit-25-4705]\]. The development of gastric cancer is a multi-factor, multi-gene and multi-step process \[[@b12-medscimonit-25-4705],[@b13-medscimonit-25-4705]\]. It is also the result of the interaction of genetic and environmental factors. It involves the activation of oncogene and inactivation of anti-oncogene, activation of telomere and gene instability. In the process of tumorigenesis and development, although the activation of oncogenes is one of the main factors to promote tumorigenesis, the inactivation of tumor suppressor genes may play a more important role \[[@b14-medscimonit-25-4705],[@b15-medscimonit-25-4705]\].

Generally, canceration seldom occurs directly from normal gastric mucosal epithelium. In most cases, the occurrence and development of gastric cancer is closely related to benign chronic gastric diseases and dysplasia of gastric mucosa. Precancerous diseases of gastric cancers refer to a number of clinical situations in which the risk of gastric cancer is significantly increased. Precancerous disease of gastric cancer includes chronic atrophic gastritis with or without intestinal metaplasia and malignant anemia, chronic gastric ulcer, remnant stomach, gastric polyp and gastric mucosal giant plica disease (Menetrier disease) after operation, and precancerous lesions of gastric cancer include gastric cancer-related diseases and dysplasia of gastric mucosa \[[@b16-medscimonit-25-4705]--[@b19-medscimonit-25-4705]\]. Gastric mucosal dysplasia is currently recognized as a precancerous lesion, especially moderate to severe dysplasia. Gastric intraepithelial neoplasia (GIN) is synonymous with dysplasia.

LPA is a multifunctional "messenger phospholipid", which can promote cell proliferation and change cell morphology. LPA is a normal component of serum, but its level in normal human plasma is extremely low \[[@b20-medscimonit-25-4705]\]. As a lipid signaling molecule, LPA can mediate various signal transduction pathways and plays its biological role by activating specific G protein-coupled receptors. There are 6 G protein-coupled receptors (GPCRs) in LPA, namely LPA1-6. Classical LPA receptors, including LPA1, LPA2, and LPA3, belong to the endothelial differentiation gene receptor (EDG) family, namely LPA1/EDG2, LPA2/EDG4, and LPA3/EDG7. LPA2 protein is encoded by the *LPA* gene, which is located in the 19.62--19.62 region of human chromosome 19. LPA2 is a G protein-coupled receptor. LPA2 binding with its ligand can activate LPA signaling pathway, thereafter, promote cell proliferation and malignant transformation \[[@b6-medscimonit-25-4705]\]. Human LPA2 protein contains 351 amino acid residues with molecular weight of 39 100. There are 3 exons and 2 introns in the coding region of *LPA2* gene. LPA1, LPA2 and LPA3 can bind to Gai/o and Gaq to regulate the signal transduction pathway of LPA.

Studies have shown that LPA2 is closely related to the occurrence of various solid tumors, such as breast cancer, ovarian cancer, colorectal cancer, pancreatic cancer, etc. \[[@b21-medscimonit-25-4705],[@b22-medscimonit-25-4705]\]. LPA2 is abnormally expressed in these tumors, and has a certain correlation with the tumor occurrence, invasion, metastasis, and prognosis.

In the present work, we found that the positive rate of LPA2 in gastric cancer tissue was significantly higher than that of GIN and normal gastric mucosa (*P*\<0.001), which was in accordance with a precious study \[[@b23-medscimonit-25-4705]\]. However, LPA2 positive expression was not correlated with age, sex, tumor location, tumor diameter, or histological grade of gastric adenocarcinoma (*P*\>0.05), but was significantly correlated with depth of invasion, Lauren classification, vascular invasion, lymph node metastasis, and clinical stage (all *P*\<0.05). The expression of LPA2 protein increased with the depth of invasion, regional lymph node metastasis, vascular invasion, Lauren's diffuse type, and clinical stage of gastric adenocarcinoma, which preliminarily indicated that the gastric adenocarcinoma with high expression of LPA2 might be more invasive, and LPA2 might be involved in the development and metastasis of gastric adenocarcinoma, which played a role in the invasion, metastasis, and progression of gastric adenocarcinoma. However, long-rank survival analysis did not find overall and DFS difference between LPA2 positive and negative groups.

The human *KLF5* gene is encoded in the 13q21 region of human chromosome. The KLF5 protein contains 457 amino acids with a molecular weight of 55 kDa. Its CDS coding region contains an activation domain and a DNA binding domain. KLF5 contains many target genes, such as nuclear factor κB (NF-κB), peroxisome proliferator-activated receptor (PPAR), platelet-derived growth factor a (pDGFa) and T cell antigen receptor (TCR), which have been confirmed in different cells. As a zinc finger transcription factor, KLF5 further participates in the regulation of cell proliferation, cell differentiation, cell apoptosis, and individual development by regulating the expression of GC-rich promoter region.

Publications have proven that KLF5 plays an important role in many malignant tumors, such as bladder cancer \[[@b24-medscimonit-25-4705]\], prostate cancer \[[@b25-medscimonit-25-4705]\], breast cancer \[[@b26-medscimonit-25-4705]\], colon cancer, thyroid cancer \[[@b27-medscimonit-25-4705]\], etc., but the biological behavior of KLF5 is different in different tumors \[[@b28-medscimonit-25-4705]\]. Nandan et al. \[[@b29-medscimonit-25-4705]\] found that KLF5 was highly expressed in the proliferative and active crypt epithelium of normal intestinal tissues. By stimulating cyclinB1, cyclinD1 and Cdc2, KLF5 accelerated cell cycle and promoted cell growth. KLF5 can promote the growth of normal cells, while KLF5 can inhibit the growth of some cancer cells, which is incomprehensible. Studies have reported that KLF5 is highly expressed in gastric adenocarcinoma \[[@b30-medscimonit-25-4705]\], but studies have also shown that the expression of KLF5 in gastric adenocarcinoma is significantly downregulated \[[@b31-medscimonit-25-4705]\]. In our study, we didn't find any correlation between KLF5 expression and patients' clinicopathological features and prognosis.

Conclusions
===========

LPA2 and KLF5 were different expressed in gastric adenocarcinoma, GIN, and normal gastric tissue. LPA2 protein is highly expressed in gastric adenocarcinoma tissues. Its positive expression is closely related to the depth of invasion, Lauren classification, vascular invasion, regional lymph node metastasis, and clinical stage. This suggests that LPA2 might be involved in the development of gastric adenocarcinoma and could be used as an important biological marker for prognosis and biological behavior of gastric cancer. However, the sample size of our study was small, and the statistical power was limited. The conclusion should be further proven by large sample sized high quality studies.
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###### 

General characteristics of the included patients.

  Characteristics         Poor differentiation (n=19)   Moderate differentiation (n=16)   Well differentiation (n=16)   High grade GIN (n=9)   Low grade GIN (n=12)   Normal (n=13)
  ----------------------- ----------------------------- --------------------------------- ----------------------------- ---------------------- ---------------------- ---------------
  Age                     57.3±7.7                      62.1±5.9                          63.2±10.3                     58.9±21.7              59.1±8.5               58.3±6.6
  Gender                                                                                                                                                              
   Male                   18                            15                                14                            7                      10                     12
   Female                 1                             1                                 2                             2                      2                      1
  Clinical stage                                                                                                                                                      
   I                      5                             5                                 12                            NA                     NA                     NA
   II                     5                             6                                 2                             NA                     NA                     NA
   III                    6                             4                                 2                             NA                     NA                     NA
   IV                     3                             1                                 0                             NA                     NA                     NA
  Tumor location                                                                                                                                                      
   Cardia                 6                             9                                 13                            NA                     NA                     NA
   Body of stomach        3                             3                                 3                             NA                     NA                     NA
   Pylorus                10                            4                                 0                             NA                     NA                     NA
  Invasion depth                                                                                                                                                      
   Mucosa or submucosa    2                             2                                 7                             NA                     NA                     NA
   Muscularis             3                             4                                 3                             NA                     NA                     NA
   Serosa                 14                            10                                6                             NA                     NA                     NA
  Lauren type                                                                                                                                                         
   Intestinal type        10                            16                                16                            NA                     NA                     NA
   Diffuse type           9                             0                                 0                             NA                     NA                     NA
  Vascular invasion                                                                                                     NA                     NA                     NA
   Yes                    8                             5                                 0                             NA                     NA                     NA
   No                     11                            11                                16                            NA                     NA                     NA
  Lymph node metastasis                                                                                                                                               
   Yes                    11                            9                                 3                             NA                     NA                     NA
   No                     8                             7                                 13                            NA                     NA                     NA
  Tumor diameter                                                                                                                                                      
   ≤5 cm                  6                             13                                12                            NA                     NA                     NA
   \>5 cm                 13                            3                                 4                             NA                     NA                     NA

###### 

LPA2 Expression in different groups (n).

  Histological category           Negative (n)   Positive (n)   Positive (%)
  ------------------------------- -------------- -------------- --------------
  Gastric adenocarcinoma                                        
   Poor (n=19)                    2              17             89.5
   Moderate (n=16)                3              13             81.3
   Well (n=16)                    12             4              25.0
  GIN                                                           
   High grade GIN (n=9)           6              3              33.3
   Low grade GIN (n=12)           9              3              25.0
   Normal gastric tissue (n=13)   10             3              23.1

LPA2 -- lysophosphatidic acid receptor-2; GIN -- gastric intraepithelial neoplasia.

###### 

Correlation between LPA2 expression and clinicopathological characteristics (n).

  Index                   N=51   LPA2   Chi-square   *P*     
  ----------------------- ------ ------ ------------ ------- ----------
  Gender                                             0.17    0.68
   Male                   47     32     15                   
   Female                 4      2      2                    
  Age (years)                                        0.30    0.59
   \<50                   8      6      2                    
   ≥50                    43     28     15                   
  Tumor location                                     0.96    0.62
   Cardia                 28     17     11                   
   Body of stomach        10     7      3                    
   Pylorus                13     10     3                    
  Lauren type                                        5.46    **0.02**
   Intestinal type        42     25     17                   
   Diffuse type           9      9      0                    
  Vascular invasion                                  5.16    **0.02**
   No                     38     22     16                   
   Yes                    13     12     1                    
  Lymph node metastasis                              7.76    **0.01**
   No                     28     14     14                   
   Yes                    23     20     3                    
  Clinical stage                                     8.71    **0.03**
   I                      22     10     12                   
   II                     13     11     2                    
   III                    12     9      3                    
   IV                     4      4      0                    
  Invasion depth                                     11.63   **0.00**
   Mucosa or submucosa    11     3      8                    
   Muscularis             10     6      4                    
   Serosa                 30     25     5                    
  Tumor diameter                                     0.02    0.89
   ≤5 cm                  35     23     12                   
   \>5 cm                 16     11     5                    
  Histological grade                                 0.00    0.96
   Well                   16     4      12                   
   Moderate               16     13     3                    
   Poor                   19     17     2                    

LPA2 -- lysophosphatidic acid receptor-2.

###### 

KLF5 expression in different groups (n).

  Histological category           Negative (n)   Positive (n)   Positive (%)
  ------------------------------- -------------- -------------- --------------
  Gastric adenocarcinoma                                        
   Poor (n=19)                    4              15             78.9
   Moderate (n=16)                4              12             75.0
   Well (n=16)                    4              12             75.0
  GIN                                                           
   High grade GIN (n=9)           3              6              66.7
   Low grade GIN (n=12)           5              7              58.3
   Normal gastric tissue (n=13)   8              5              38.5

KLF5 -- Krüppel-like factor 5; GIN -- gastric intraepithelial neoplasia.

###### 

Correlation between KLF5 expression and clinicopathological characteristics (n).

  Index                   N=51   KLF5   Chi-square   *P*    
  ----------------------- ------ ------ ------------ ------ ------
  Gender                                             0.01   0.94
   Male                   47     36     11                  
   Female                 4      3      1                   
  Age (years)                                        0.64   0.42
   \<50                   8      7      1                   
   ≥50                    43     32     11                  
  Tumor location                                     0.46   0.79
   Cardia                 28     22     6                   
   Body of stomach        10     8      2                   
   Pylorus                13     9      4                   
  Lauren type                                        0.01   0.92
   Intestinal type        42     32     10                  
   Diffuse type           9      7      2                   
  Vascular invasion                                  0.51   0.48
   No                     38     30     8                   
   Yes                    13     9      4                   
  Lymph node metastasis                              0.88   0.35
   No                     28     20     8                   
   Yes                    23     19     4                   
  Clinical stage                                     5.41   0.14
   I                      22     16     6                   
   II                     13     12     1                   
   III                    12     7      5                   
   IV                     4      4      0                   
  Invasion depth                                     1.28   0.53
   Mucosa or submucosa    11     7      4                   
   Muscularis             30     24     6                   
   Serosa                 10     8      2                   
  Tumor diameter                                     1.59   0.21
   ≤5 cm                  37     30     7                   
   \>5 cm                 14     9      5                   
  Histological grade                                 0.07   0.78
   Well                   16     12     4                   
   Moderate               16     12     4                   
   Poor                   19     15     4                   

KLF5 -- Krüppel-like factor 5.
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